ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Cysteine-Rich Protein Prevents Weight Loss In Lung Cancer Patients: A Promising Intervention Study
Immunotec Inc. (TSX-V: IMM)
announced the successful completion of a multi-center randomized,
double blind clinical trial on cancer-related weight loss (cachexia) in
lung cancer patients which was performed in collaboration with various
Canadian clinical centers(x). The research concluded that patients treated
with IMN 1207 showed significant increases in body weight (Tozer et al.
Antioxidants & Redox Signaling (2008) 10:395-402). Immunotec also announced
the initiation of a follow-up study to confirm the positive results.
The massive loss of body weight and muscle mass in advanced cancer
patients is typically associated with psychological stress, financial
burden and a decreased quality of life. Until now there have been no
dietary interventions known to satisfactorily prevent this process.
Immunotec's new study included 66 patients with advanced lung cancer
receiving state of the art chemotherapy or radiotherapy. The patients had
already suffered significant involuntary weight-loss prior to treatment.
During a six month treatment period the patients were given either casein,
a protein supplement low in cysteine which is widely used in clinical
nutrition ("placebo") or IMN 1207, a specially-prepared glutathione
enhancing cysteine-rich whey protein isolate supplied by Immunotec Inc. The
results showed that patients in the placebo group continued to lose weight
whereas patients treated with IMN 1207 showed a significant increase in
body weight. Incidentally, these patients also showed an increase in
strength and quality of life parameters. This study showed for the first
time that cancer-related weight loss (cachexia) can be prevented by a
single source of protein. Dr. Gerald Batist, Chair, Department of Oncology,
McGill University stated "Having been involved in the early mechanistic
studies of the therapeutic use of whey proteins, I'm pleased to see this
particular formulation being tested in the clinic. The data to date
encourage additional and expanded clinical trials". Dr. Wulf Droge, Senior
Vice-President Research & Development at Immunotec Inc. emphasized that the
results of this first trial should be viewed with cautious optimism. A
second trial has been initiated to confirm the results.
Among other questions, this clinical trial also addressed the
controversy about antioxidant use in chemotherapy. Since radiotherapy and
many types of chemotherapy work by raising levels of oxidative stress and
free radical formation to destroy cancer cells, oncologists have voiced
concern that treatment of the patient with antioxidants may "protect" the
cancer from the toxic effects of the therapy. If this were the case,
antioxidants could even be expected to shorten the life span of the
patients. Immunotec's study now showed that this was clearly not the case
with IMN 1207. Based on his earlier work at his laboratory at the National
Cancer Research Center of Germany (DKFZ) in Heidelberg, Dr. Droge was
reasonably confident that supplementation with a critical precursor of the
major cellular antioxidant glutathione, would actually improve the
condition of the patients, most probably by ameliorating adverse effects of
these therapies on the patients' healthy tissues. The results of this new
study suggest that this is true. The antioxidant glutathione is distinct
from other antioxidants including the popular antioxidant vitamins A, C,
and E which are widely used as nutritional supplements. Glutathione is
involved in the removal of reactive oxygen species and other potential
toxic compounds through special biochemical processes and can reach
relatively high and beneficial concentrations in cells and tissues
depending on the availability of its biosynthetic precursor cysteine.
About IMN 1207
IMN 1207 is a cysteine-rich protein. It is the research formulation of
the undenatured whey protein Immunocal(R)/HMS 90(R), a dietary natural
health supplement, developed and marketed worldwide by Immunotec during the
past 12 years. Immunocal(R)/HMS 90 is a precursor of the major cellular
antioxidant glutathione, an element important in maintaining a strong
immune system.
About Immunotec Inc.
Immunotec is engaged primarily in the development and marketing of
natural health products, dietary supplements, food, vitamins and personal
care products, many of which are manufactured on its behalf by third
parties. Immunotec's products are distributed and sold in Canada and the
United States through a network marketing system and in other countries
through exclusive distributorship agreements. Immunotec's investment in
this study is another manifestation of its ongoing commitment to research
and development. http://www.immunotec.com.
- (x) Montreal General Hospital (McGill University teaching hospital)
Montreal, Quebec, Canada
- (x) Cross Cancer Institute, Alberta Cancer Board (University of Alberta
affiliate) Edmonton, Alberta, Canada
- (x) Jewish General Hospital (McGill University teaching hospital)
Montreal, Quebec, Canada
- (x) Juravinski Cancer Centre (McMaster University and Hamilton Health
Sciences affiliate) Hamilton, Ontario,Canada.
- (x) Allan Blair Cancer Centre (a division of Saskatchewan Cancer
Foundation) Regina, Saskatchewan, Canada.
MMUNOTEC INC.
http://www.immunotec.com
Cisteina-Rich Protein Previne Greutate Pierdere În Cancerul pulmonar Pacienþii: Un promitator Studiul de intervenþie - Cysteine-Rich Protein Prevents Weight Loss In Lung Cancer Patients: A Promising Intervention Study - articole medicale engleza - startsanatate